

Michael M Mcneil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7522471/publications.pdf>

Version: 2024-02-01

106
papers

5,044
citations

117453

34
h-index

95083

68
g-index

107
all docs

107
docs citations

107
times ranked

4325
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997. <i>Clinical Infectious Diseases</i> , 2001, 33, 641-647.	2.9	566
2	Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol. <i>New England Journal of Medicine</i> , 1995, 333, 147-154.	13.9	516
3	Risk of anaphylaxis after vaccination in children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 868-878.	1.5	298
4	An Epidemic of <i>Malassezia pachydermatis</i> in an Intensive Care Nursery Associated with Colonization of Health Care Workers' Pet Dogs. <i>New England Journal of Medicine</i> , 1998, 338, 706-711.	13.9	253
5	Vaccine-associated hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 463-472.	1.5	193
6	The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. <i>Vaccine</i> , 2014, 32, 5390-5398.	1.7	175
7	Guideline for Prevention of Nosocomial Pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 1994, 15, 587-627.	1.0	149
8	Taxonomic variation in the <i>Mycobacterium fortuitum</i> third biovariant complex: description of <i>Mycobacterium boenickei</i> sp. nov., <i>Mycobacterium houstonense</i> sp. nov., <i>Mycobacterium neworleansense</i> sp. nov. and <i>Mycobacterium brisbanense</i> sp. nov. and recognition of <i>Mycobacterium porcinum</i> from human clinical isolates. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2004, 54, 1653-1667.	0.8	119
9	Guideline for Prevention of Nosocomial Pneumonia. <i>Infection Control and Hospital Epidemiology</i> , 1994, 15, 587-627.	1.0	118
10	Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010. <i>Vaccine</i> , 2010, 28, 7248-7255.	1.7	115
11	A Cluster of <i>Rhodococcus (Gordona) bronchialis</i> Sternal-Wound Infections after Coronary-Artery Bypass Surgery. <i>New England Journal of Medicine</i> , 1991, 324, 104-109.	13.9	114
12	Nosocomial <i>Malassezia pachydermatis</i> bloodstream infections in a neonatal intensive care unit. <i>Pediatric Infectious Disease Journal</i> , 1994, 13, 104-108.	1.1	106
13	Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 802-812.	4.6	102
14	Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1581.	3.8	91
15	Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 Months _{title} _{title}. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1532.	3.8	90
16	Abscesses due to <i>Mycobacterium abscessus</i> Linked to Injection of Unapproved Alternative Medication. <i>Emerging Infectious Diseases</i> , 1999, 5, 681-687.	2.0	86
17	Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. <i>Obstetrics and Gynecology</i> , 2015, 126, 1069-1074.	1.2	86
18	Outbreak of Sporotrichosis among Tree Nursery Workers. <i>Journal of Infectious Diseases</i> , 1997, 176, 499-504.	1.9	71

#	ARTICLE	IF	CITATIONS
19	Characterization of clinical isolates previously identified as <i>Oerskovia turbata</i> : proposal of <i>Cellulosimicrobium funkei</i> sp. nov. and emended description of the genus <i>Cellulosimicrobium</i> . <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2006, 56, 801-804.	0.8	69
20	<i>Candida parapsilosis</i> Bloodstream Infections in Neonatal Intensive Care Unit Patients: Epidemiologic and Laboratory Confirmation of a Common Source Outbreak. <i>Pediatric Infectious Disease Journal</i> , 1996, 15, 998-1002.	1.1	69
21	Microbial Growth and Endotoxin Production in the Intravenous Anesthetic Propofol. <i>Infection Control and Hospital Epidemiology</i> , 1991, 12, 535-539.	1.0	68
22	U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. <i>Vaccine</i> , 2021, 39, 3666-3677.	1.7	61
23	Use of a Repetitive DNA Probe To Type Clinical and Environmental Isolates of <i>Aspergillus flavus</i> from a Cluster of Cutaneous Infections in a Neonatal Intensive Care Unit. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3612-3618.	1.8	60
24	Investigation of an epidemic of invasive aspergillosis. <i>Pediatric Infectious Disease Journal</i> , 1994, 13, 386-393.	1.1	54
25	Cluster of Cases of Invasive Aspergillosis in a Transplant Intensive Care Unit: Evidence of Person-to-Person Airborne Transmission. <i>Clinical Infectious Diseases</i> , 2002, 34, 412-416.	2.9	51
26	Evaluation of Therapy for <i>Nocardia asteroides</i> Complex Infections. <i>Infectious Diseases in Clinical Practice</i> , 1995, 4, 287.	0.1	49
27	Anxiety-related adverse events following immunization (AEFI): A systematic review of published clusters of illness. <i>Vaccine</i> , 2018, 36, 299-305.	1.7	46
28	Risk of Nontargeted Infectious Disease Hospitalizations Among US Children Following Inactivated and Live Vaccines, 2005-2014. <i>Clinical Infectious Diseases</i> , 2017, 65, 729-737.	2.9	45
29	Phenotypic and Genetic Characterization of Clinical Isolates of CDC Coryneform Group A-3: Proposal of a New Species of <i>Cellulomonas</i> , <i>Cellulomonas denverensis</i> sp. nov. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1732-1737.	1.8	40
30	Adverse events following measles, mumps, and rubella vaccine in adults reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013. <i>Clinical Infectious Diseases</i> , 2015, 60, e58-65.	2.9	40
31	Central Venous Catheter Sepsis Caused by Unusual <i>Gordona</i> (<i>Rhodococcus</i>) Species: Identification with a Digoxigenin-Labeled rDNA Probe. <i>Clinical Infectious Diseases</i> , 1992, 15, 694-697.	2.9	39
32	Anthrax Vaccination and Risk of Optic Neuritis in the United States Military, 1998-2003. <i>Archives of Neurology</i> , 2006, 63, 871.	4.9	39
33	Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Intervention. <i>Journal of Adolescent Health</i> , 2017, 61, 252-258.	1.2	38
34	Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings. <i>JAMA Pediatrics</i> , 2018, 172, 469.	3.3	38
35	Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 928-934.	0.9	35
36	White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. <i>Vaccine</i> , 2016, 34, A1-A29.	1.7	35

#	ARTICLE	IF	CITATIONS
37	Rapid Identification of <i>Nocardia farcinica</i> Clinical Isolates by a PCR Assay Targeting a 314-Base-Pair Species-Specific DNA Fragment. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3655-3660.	1.8	33
38	Association between parent attitudes and receipt of human papillomavirus vaccine in adolescents. <i>BMC Public Health</i> , 2017, 17, 766.	1.2	33
39	The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome. <i>Vaccine</i> , 2020, 38, 7458-7463.	1.7	31
40	Microbial Growth and Endotoxin Production in the Intravenous Anesthetic Propofol. <i>Infection Control and Hospital Epidemiology</i> , 1991, 12, 535-539.	1.0	30
41	Postsurgical <i>Candida albicans</i> Infections Associated with an Extrinsically Contaminated Intravenous Anesthetic Agent. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1398-1403.	1.8	29
42	Who is unlikely to report adverse events after vaccinations to the Vaccine Adverse Event Reporting System (VAERS)?. <i>Vaccine</i> , 2013, 31, 2673-2679.	1.7	28
43	Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015. <i>Vaccine</i> , 2017, 35, 1758-1763.	1.7	28
44	Vaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002-2008. <i>Vaccine</i> , 2012, 30, 813-819.	1.7	27
45	<i>Aspergillus fumigatus</i> Sternal Wound Infections in Patients undergoing Open Heart Surgery. <i>American Journal of Epidemiology</i> , 1992, 135, 48-58.	1.6	26
46	Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 259-274.	0.9	25
47	Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. <i>Vaccine</i> , 2014, 32, 3548-3554.	1.7	25
48	Serious Adverse Events among Participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for Persons at Risk for Bioterrorism-Related Inhalational Anthrax. <i>Clinical Infectious Diseases</i> , 2003, 37, 905-911.	2.9	22
49	Molecular Epidemiologic Evaluation of Endocarditis Due to <i>Oerskovia turbata</i> and CDC Group A-3 Associated with Contaminated Homograft Valves. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2495-2500.	1.8	22
50	Acute pulmonary histoplasmosis in bridge workers: a persistent problem. <i>American Journal of Medicine</i> , 1999, 106, 480-482.	0.6	21
51	Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 391-397.	0.9	21
52	Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018. <i>Vaccine</i> , 2019, 37, 6760-6767.	1.7	21
53	Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 46-54.	0.9	20
54	Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013. <i>Vaccine</i> , 2014, 32, 6499-6504.	1.7	19

#	ARTICLE	IF	CITATIONS
55	Ischemic cardiac events and other adverse events following ACAM2000® smallpox vaccine in the Vaccine Adverse Event Reporting System. <i>Vaccine</i> , 2014, 32, 4758-4765.	1.7	19
56	The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2872-2879.	1.4	18
57	An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 393-401.	0.9	17
58	Cluster anxiety-related adverse events following immunization (AEFI): An assessment of reports detected in social media and those identified using an online search engine. <i>Vaccine</i> , 2018, 36, 5949-5954.	1.7	17
59	Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention. <i>Expert Review of Vaccines</i> , 2019, 18, 1091-1101.	2.0	17
60	The use of natural language processing to identify vaccine-related anaphylaxis at five health care systems in the Vaccine Safety Datalink. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 182-188.	0.9	17
61	The epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Newsletter</i> , 1985, 2, 49.	0.9	16
62	Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program. <i>Pharmacoepidemiology and Drug Safety</i> , 2006, 15, 880-888.	0.9	16
63	Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44 years reported to the Vaccine Adverse Event Reporting System. <i>Vaccine</i> , 2016, 34, 4406-4414.	1.7	15
64	Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule. <i>Vaccine</i> , 2017, 35, 1873-1878.	1.7	15
65	Human Papillomavirus Vaccine Coverage and Prevalence of Missed Opportunities for Vaccination in an Integrated Healthcare System. <i>Academic Pediatrics</i> , 2018, 18, S85-S92.	1.0	14
66	NOCARDIA TRANSVALENSIS PNEUMONIA IN A CHILD. <i>Pediatric Infectious Disease Journal</i> , 1989, 8, 470.	1.1	13
67	Assessment of anthrax vaccination data in the Defense Medical Surveillance System, 1998-2004. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 605-611.	0.9	13
68	Integration of data from a safety net health care system into the Vaccine Safety Datalink. <i>Vaccine</i> , 2017, 35, 1329-1334.	1.7	13
69	Persistence of Oropharyngeal <i>Candida albicans</i> Strains with Reduced Susceptibilities to Fluconazole among Human Immunodeficiency Virus-Seropositive Children and Adults in a Long-Term Care Facility. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1833-1837.	1.8	12
70	Trends in prescribing for vulvovaginal candidiasis in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 113-120.	0.9	12
71	Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 1060-1067.	0.9	12
72	Vaccine adverse events in a safety net healthcare system and a managed care organization. <i>Vaccine</i> , 2017, 35, 1335-1340.	1.7	12

#	ARTICLE	IF	CITATIONS
73	Phenotypic and molecular epidemiologic evaluation of a <i>Nocardia farcinica</i> mastitis epizootic. <i>Veterinary Microbiology</i> , 2007, 125, 66-72.	0.8	11
74	Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults. <i>Pediatrics</i> , 2016, 137, e20152970.	1.0	11
75	Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less. <i>Expert Review of Vaccines</i> , 2016, 15, 1151-1162.	2.0	11
76	Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule. <i>Academic Pediatrics</i> , 2018, 18, 754-762.	1.0	11
77	Vaccine-Associated Anaphylaxis. <i>Current Treatment Options in Allergy</i> , 2019, 6, 297-308.	0.9	10
78	Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016. <i>Vaccine</i> , 2020, 38, 6291-6298.	1.7	10
79	Temporal Trends in Undervaccination: A Population-Based Cohort Study. <i>American Journal of Preventive Medicine</i> , 2021, 61, 64-72.	1.6	9
80	Concurrent Vaccinations and U.S. Military Hospitalizations. <i>Annals of Epidemiology</i> , 2007, 17, 697-703.	0.9	8
81	A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination- Possible stimulated reporting?. <i>Vaccine</i> , 2012, 30, 2421-2426.	1.7	8
82	Continuous sequential boundaries for vaccine safety surveillance. <i>Statistics in Medicine</i> , 2014, 33, 3387-3397.	0.8	7
83	Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case-Control Study. <i>Military Medicine</i> , 2016, 181, 1348-1356.	0.4	7
84	Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 921-925.	0.9	7
85	Successes of the CDC monitoring systems in evaluating post-authorization safety of COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 281-284.	2.0	7
86	Risk of Fatal Adverse Events after H1N1 Influenza Vaccine: Limitations of Passive Surveillance Data. <i>Clinical Infectious Diseases</i> , 2010, 51, 871-872.	2.9	6
87	Assessing Agreement of Repeated Binary Measurements with an Application to the CDC's Anthrax Vaccine Clinical Trial. <i>International Journal of Biostatistics</i> , 2013, 9, .	0.4	6
88	Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the Vaccine Safety Datalink. <i>Vaccine</i> , 2022, 40, 3064-3071.	1.7	6
89	Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial. <i>Vaccine</i> , 2012, 30, 5875-5879.	1.7	5
90	Military Healthcare Providers Reporting of Adverse Events Following Immunizations to the Vaccine Adverse Event Reporting System. <i>Military Medicine</i> , 2014, 179, 435-441.	0.4	5

#	ARTICLE	IF	CITATIONS
91	Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the Vaccine Adverse Event Reporting System (VAERS), 2008–2016. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-5.	1.4	5
92	Sociodemographic and clinical correlates of human papillomavirus vaccine attitudes and receipt among Wisconsin adolescents. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100168.	4.5	5
93	Vaccination and risk of lone atrial fibrillation in the active component United States military. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 669-676.	1.4	5
94	Quality assessment of nonanthrax vaccination data in the Defense Medical Surveillance System (DMSS), 1998–2004. <i>Vaccine</i> , 2008, 26, 1577-1584.	1.7	4
95	Health-related quality of life in the Anthrax Vaccination Program for workers in the Laboratory Response Network. <i>Vaccine</i> , 2012, 30, 1841-1846.	1.7	4
96	Vulvovaginal Candidiasis: Available Therapeutic Options. <i>Infectious Diseases in Clinical Practice</i> , 1995, 4, 36-40.	0.1	3
97	A Pseudoepidemic of Postoperative Scleritis Due to Misdiagnosis. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 539-542.	1.0	3
98	A comparative assessment of immunization records in the Defense Medical Surveillance System and the Vaccine Adverse Event Reporting System. <i>Vaccine</i> , 2007, 25, 3428-3436.	1.7	3
99	Current safety issues with quadrivalent meningococcal conjugate vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1175-1178.	1.4	3
100	<i>Notes from the Field</i>: Errors in Administration of an Excess Dosage of Yellow Fever Vaccine – United States, 2017. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 109-110.	9.0	3
101	Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. <i>Vaccine</i> , 2022, 40, 2568-2573.	1.7	2
102	Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero. <i>Pediatrics</i> , 0, , .	1.0	2
103	Influenza Vaccination Among Pregnant Women: Self-report Compared With Vaccination Data From Electronic Health Records, 2018-2020 Influenza Seasons. <i>Public Health Reports</i> , 2023, 138, 456-466.	1.3	2
104	Optic Neuritis and Vaccination Investigation: Failure to Consider Significant Sex Differences and Multiple Vaccine Combinations—Reply. <i>Archives of Neurology</i> , 2007, 64, 1674.	4.9	1
105	Association of TDAP Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 1-2.	0.2	0
106	Reply to Burgner, et al. <i>Clinical Infectious Diseases</i> , 2018, 66, 319-319.	2.9	0